GSDMD and Hepatic fibrosis: Of note, our data revealed that lnc-Lfar1 silencing inhibited pyroptosis in vivo and in vitro as assessed by the level of pyroptosis-related proteins including NLRP3, pro-caspase-1, cleaved caspase1, GSDMD and GSDMD-N, mature IL-1β, IL-18 and the released LDH, further confirming that lnc-Lfar1 may represent a therapeutic target for inflammasome associated diseases such as liver fibrosis.